ESC 365 - Evaluation of disease progression in patients with ATTR amyloidosis with cardiomyopathy following treatment with patisiran: post-hoc analysis of the APOLLO-B study

ESC Professional Premium Access

Evaluation of disease progression in patients with ATTR amyloidosis with cardiomyopathy following treatment with patisiran: post-hoc analysis of the APOLLO-B study

Session: Heart failure red flags and their management

Topic: Pharmacotherapy

Speaker: Professor T. Damy (Creteil, FR)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor Thibaud Damy

University Hospital Henri Mondor, Creteil (France)

37 presentations

1 follower

5 more presentations in this session

Acoramidis produces near-complete TTR stabilization in blood samples from patients with variant transthyretin amyloidosis that is greater than that achieved with tafamidis

Speaker: Mr A. Ji (San Francisco, US)

The use of 99mTc-PYP SPECT/CT in monitoring therapeutic changes of eplontersen in patients with hereditary transthyretin cardiomyopathy

Speaker: Doctor A. Yu (Taipei, TW)

The role of infliximab in treating refractory cardiac sarcoidosis

Speaker: Doctor R. Ahmed (London, GB)

Survival analysis of tafamidis use in patients with ATTR cardiac amyloidosis

Speaker: Doctor N. Starr (Co. Limerick, IE)

Non-adherence to prescribed medications in ambulatory patients with heart failure assessed using liquid chromatography tandem mass spectrometry

Speaker: Doctor S. Sze (Leicester, GB)

Access the full session

Heart failure red flags and their management

Speakers: Professor T. Damy, Mr A. Ji, Doctor A. Yu, Doctor R. Ahmed, Doctor N. Starr...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources